Understanding how leukemia cells communicate with immune cells during CAR T-cell therapy

Map Leukemia-immune Cell Talks with Nanoplasmon Ruler in CAR T-Cell Immunotherapy

NIH-funded research New York University · NIH-10875282

This study is looking at how special immune cells called CAR T-cells interact with leukemia cells in patients with B-cell acute lymphoblastic leukemia, aiming to find better ways to make these treatments work more effectively and reduce side effects.

Quick facts

Grant typeR01 grant
Study typeNIH-funded research
Funding institutionNew York University NIH-funded
Lab location1 site (New York, United States)
Project IDNIH-10875282 on NIH RePORTER

What this research studies

This research investigates the interactions between leukemia cells and immune cells, specifically focusing on CAR T-cells that are engineered to target CD19 in patients with B-cell acute lymphoblastic leukemia (B-ALL). The study aims to develop a novel technique using a nanoplasmon ruler to monitor the real-time communication and cytokine secretion between these cells in the tumor microenvironment. By gaining insights into these interactions, the research seeks to improve the effectiveness of CAR T-cell therapy and address issues such as poor T-cell function and cytokine release syndrome. Patients may benefit from a better understanding of how to enhance CAR T-cell therapies for more effective treatment outcomes.

Who could benefit from this research

Good fit: Ideal candidates for this research are individuals diagnosed with B-cell acute lymphoblastic leukemia who are considering or undergoing CAR T-cell therapy.

Not a fit: Patients with other types of leukemia or those who are not eligible for CAR T-cell therapy may not benefit from this research.

Why it matters

Potential benefit: If successful, this research could lead to improved CAR T-cell therapies for patients with B-ALL, enhancing treatment efficacy and reducing side effects.

How similar studies have performed: Other research has shown promise in enhancing CAR T-cell therapies, but the specific approach of using a nanoplasmon ruler for real-time monitoring is relatively novel.

Where this research is happening

New York, United States

Researchers

About this research

  1. This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
  2. Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
  3. For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Last reviewed 2026-06-13 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.